Experience

Fraunhofer Institute for Cell Therapy and Immunology
• Arbeitsgruppenleiter


Fraunhofer IZI

• Germany
• Biotechnology Research
• 100 - 200 Employee

• Vice head Dept. Cell Engineering, Head Cell Engineering/GLP unit

  • 2006 - Present

  The Fraunhofer Institute for Cell Therapy and Immunology (Fraunhofer-IZI, www.izi.fraunhofer.de), founded in 2005, is located in Leipzig, Germany and belongs to the Fraunhofer Life Science Alliance. This institute develops methods and models for regenerative medicine. Fundamental departments are stem cell biology, vascular biology, vaccine development, tolerance induction, cell technologies and GLP and finally the GMP unit for manufacturing of cell therapeutics and biologics. The IZI Cell Technology / GLP unit, lead by Dr. Jörg Lehmann, is developing disease-related biobanks: (I) for specimens from patients with chronic inflammatory bowel diseases (IBD) and relevant control subjects; (II) for synovial fibroblasts from patients with rheumatoid arthritis (RA) or diseases with similar symptoms such as osteoarthritis (OA); (III) for breath condensate samples from patients with lung cancer or COPD. Using these biobanks, the group intends to identify and validate novel biomarkers for chronic inflammatory diseases (i.e. IBD, RA) or lung cancer. Methods required for pre- and post-banking analytics (i.e. differential proteom analysis by 2D-GE/DIGE or MALDI-TOF/ESI technology (in cooperation with PD Dr. M. v. Bergen, UFZ, Leipzig), cellular analysis by flow cytometry and real-time cell analysis, immunochemical techniques such as western blot, ELISA, protein array, or immunocytochemistry, and Real-time RT-PCR) are established in a GLP-conform fashion. In August 2009 the department has been GLP-certified for immunotoxicology/immunogenicity in vitro. Other expertises of the unit concern to QC assay development and validation, generation of monoclonal antibodies and cell separation. Show less